SGI,VWR Announce Agreement
News Jul 22, 2016
SGI-DNA has announced that it has entered into an exclusive distribution agreement for its reagents portfolio with VWR to laboratory and production facilities. This agreement with VWR makes SGI-DNA reagents more readily available by leveraging VWR’s network across North America and Europe. "We are excited to add SGI-DNA to our life science portfolio," said Stephan Labonté, SVP Marketing for VWR. "SGI-DNA’s innovative technologies allow VWR to better support our customers in the rapidly developing field of synthetic biology."
A key technology distributed through this agreement is Gibson Assembly® DNA cloning methodology. SGI-DNA’s complete suite of 3 products, the HiFi 1-Step, Ultra, and Site-Directed Mutagenesis Gibson Assembly Kits, will be made available to VWR customers as part of this agreement. Previously, reagents manufactured by SGI-DNA were only available by directly ordering from the company.
Gibson Assembly methodologies were developed in 2009 by Dan Gibson and his colleagues at the J. Craig Venter Institute along with SGI. This revolutionary approach to creating plasmid DNA clones allows the assembly of multiple DNA fragments in a single reaction without the need for compatible restriction sites. Gibson Assembly is significantly faster and much more efficient than traditional restriction enzyme digest-based cloning and proven for the cloning of both small and large double stranded DNA fragments.
The Gibson Assembly method is supported by over 1,200 peer reviewed publications and is proven for the generation of DNA constructs and libraries as well as for pathway engineering and other synthetic biology applications.
Key advantages of Gibson Assembly:
• Simple — A one tube reaction joins DNA ends without need for restriction enzyme site compatibility
• Enables complex constructs — Assemble up to 15 double stranded DNA fragments at a time
• Fast — Generates transformation ready constructs in about an hour
• Flexible — Creates seamless, error-free constructions without the presence of extraneous or intervening sequences such as restriction sites
Nathan Wood, President, SGI-DNA, said, "This agreement represents a major milestone for SGI-DNA as it greatly improves our potential to commercialize our technologies through established VWR channels. This VWR/SGI-DNA agreement will also benefit life science researchers as they’ll have better access to Gibson Assembly® reagents for more streamlined molecular biology workflows."
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019